doi: 10.1161/CIRCULATIONAHA.105.170815
(Circulation. 2006;113:156-175.)
© 2006 American Heart Association, Inc.
ACC/AHA/SCAI Practice Guideline |
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article
A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
 |
Introduction |
|---|
 Top Introduction Appendix.References |
|---|
The American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) 2005 Guideline Update for Percutaneous Coronary Intervention (PCI) contains changes in the recommendations, along with supporting text. For the purpose of comparison, this summary contains a list of the updated recommendations (middle column) alongside a list of the 2001 recommendations (left column), with each set accompanied by a comment (right column) that provides the rationale for the changes, additions, or deletions (see Table 1
). References that support either the 2001 recommendations that have changed or the new or revised recommendations are cited in parentheses at the end of each recommendation or comment. A list of abbreviations is included in the Appendix. The reader is referred to the full-text guideline posted on the World Wide Web sites of the ACC, the AHA, and the SCAI for a more detailed explanation of the changes discussed here. Please note that we have changed the table of contents headings in the 2001 ACC/AHA Guidelines for Percutaneous Coronary Intervention from roman numerals to unique identifying numbers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In preparing this update, the committee was guided by the following principles:
- Changes in recommendations and levels of evidence were made because of the availability of data from new randomized trials, the accumulation of new clinical evidence, and/or the development of clinical consensus.
- The committee is cognizant of the healthcare, logistic, and financial implications of recent trials and factored in these considerations in arriving at the class level of certain recommendations.
- All recommendations in the PCI guideline update have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document, will still convey the full intent of the recommendation.
- The committee wishes to re-emphasize that the recommendations in the guideline apply to most patients but may require modification by existing situations that only the primary treating healthcare provider can evaluate properly.
- The committee endeavored to maintain the consistency of recommendations in this and other previously published guidelines, primarily the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and the ACC/AHA 2002 Guideline Update for the Management of Patients With Non–ST-Elevation Myocardial Infarction.
The classification of recommendations and levels of evidence are expressed in the ACC/AHA format as follows:
Classification of Recommendations
- Class I:Conditions for which there is evidence for and/or general agreement that a given procedure or treatment is beneficial, useful, and effective.
- Class II:Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.
- IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.
- IIb: Usefulness/efficacy is less well established by evidence/opinion.
- IIb: Usefulness/efficacy is less well established by evidence/opinion.
- Class III: Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful.
- Class II:Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.
Level of Evidence
- Level of Evidence A:Data derived from multiple randomized clinical trials or meta-analyses.
- Level of Evidence B:Data derived from a single randomized trial or nonrandomized studies.
- Level of Evidence C:Only consensus opinion of experts, case studies, or standard-of-care.
- Level of Evidence B:Data derived from a single randomized trial or nonrandomized studies.
|
Appendix. |
|---|
|
TopIntroductionAppendix.References |
|---|
Abbreviations
- CABG coronary artery bypass graft surgery
- CAD coronary artery disease
- CK creatine kinase
- DES drug-eluting stent
- ECG electrocardiogram
- GP glycoprotein
- HF heart failure
- IVUS intravascular ultrasound
- LAD left anterior descending artery
- LBBB left bundle-branch block
- LV left ventricular
- MB cardiac muscle isoenzyme of creatine kinase
- MI myocardial infarction
- MR mitral regurgitation
- NSTEMI non–ST-elevation myocardial infarction
- PCI percutaneous coronary intervention
- STEMI ST-elevation myocardial infarction
- UA unstable angina
- CAD coronary artery disease
|
Footnotes |
|---|
*Official SCAI representative.
Former Task Force Member during this writing effort.
Acknowledgment: The ACC and AHA recognize Dr J. Ward Kennedy for his dedicated service on developing ACC/AHA guidelines for PTCA and PCI since their inception in 1986 and for his counsel and advice in the preparation of this guideline.
This document was approved by the American College of Cardiology Foundation Board of Trustees in September 2005, by the American Heart Association Science Advisory and Coordinating Committee in September 2005, and by the Society for Cardiovascular Angiography and Interventions in September 2005.
The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. The relationship with industry information for writing committee members, as well as peer reviewers of the document, is located in an appendix of the full-text guideline, which is available on the ACC, AHA, and SCAI Web sites.
When citing this document, the American Heart Association requests that the following citation format be used: Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O’Neill WW, Schaff HV, Whitlow PL, Williams DO. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:156–175.
Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org), the American Heart Association (www.americanheart.org), and the Society for Cardiovascular Angiography and Interventions (www.scai.org). Single copies of this document are available by calling 1-800-253-4636 or writing the American College of Cardiology Foundation, Resource Center, at 9111 Old Georgetown Road, Bethesda, MD 20814-1699. Ask for reprint number 71-0346. To obtain a copy of the full text published in the January 3, 2006, issue of the Journal of the American College of Cardiology, the January 3, 2006, issue of Circulation, and the January 2006, issue of Catheterization and Cardiovascular Interventions, ask for reprint number 71-0347. To purchase bulk reprints (specify version and reprint number): Up to 999 copies, call 1-800-611-6083 US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1789, fax 214-691-6342, or e-mail pubauth@heart.org.
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please direct requests to copyright_permissions@acc.org.
© 2006 by the American College of Cardiology Foundation and the American Heart Association, Inc.
|
References |
|---|
|
TopIntroductionAppendix.References |
|---|
1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000; 36: 959–69.
2. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation. 2005; 111: 1027–32.
3. Bertinchant JP, Polge A, Ledermann B, et al. Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol. 1999; 84: 51–7.[CrossRef][Medline] [Order article via Infotrieve]
4. Garbarz E, Iung B, Lefevre G, et al. Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. Am J Cardiol. 1999; 84: 515–8.[CrossRef][Medline] [Order article via Infotrieve]
5. Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol. 2000; 85: 1077–82.[CrossRef][Medline] [Order article via Infotrieve]
6. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol. 2002; 39: 1738–44.
7. Wu AH, Boden WE, McKay RG. Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. Am J Cardiol. 2002; 89: 1300–2.[CrossRef][Medline] [Order article via Infotrieve]
8. Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J. 2003; 24: 1314–22.
9. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J. 2003; 145: 522–8.[CrossRef][Medline] [Order article via Infotrieve]
10. Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 2004; 93: 18–23.[Medline] [Order article via Infotrieve]
11. Vakili BA, Kaplan R, Brown DL. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation. 2001; 104: 2171–6.
12. Vakili BA, Brown DL. Relation of total annual coronary angioplasty volume of physicians and hospitals on outcomes of primary angioplasty for acute myocardial infarction (data from the 1995 Coronary Angioplasty Reporting System of the New York State Department of Health). Am J Cardiol. 2003; 91: 726–8.[CrossRef][Medline] [Order article via Infotrieve]
13. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000; 283: 2941–7.
14. Jollis JG, Peterson ED, Nelson CL, et al. Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patients. Circulation. 1997; 95: 2485–91.
15. Klein LW, Schaer GL, Calvin JE, et al. Does low individual operator coronary interventional procedural volume correlate with worse institutional procedural outcome? J Am Coll Cardiol. 1997; 30: 870–7.[Abstract]
16. Magid DJ, Calonge BN, Rumsfeld JS, et al. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA. 2000; 284: 3131–8.
17. Canto JG, Every NR, Magid DJ, et al. The volume of primary angioplasty procedures and survival after acute myocardial infarction: National Registry of Myocardial Infarction 2 Investigators. N Engl J Med. 2000; 342: 1573–80.
18. Klinke WP, Hui W. Percutaneous transluminal coronary angioplasty without on-site surgical facilities. Am J Cardiol. 1992; 70: 1520–5.[CrossRef][Medline] [Order article via Infotrieve]
19. Meier B, Urban P, Dorsaz PA, Favre J. Surgical standby for coronary balloon angioplasty. JAMA. 1992; 268: 741–5.
20. Iniguez A, Macaya C, Hernandez R, et al. Comparison of results of percutaneous transluminal coronary angioplasty with and without selective requirement of surgical standby. Am J Cardiol. 1992; 69: 1161–5.[CrossRef][Medline] [Order article via Infotrieve]
21. Hubner PJ, Balcon R, Dyet J, Dymond DS, et al. Surgical cover for percutaneous transluminal coronary angioplasty. Br Heart J. 1992; 68: 339–41.
22. Sowton E, de Bono D, Gribbin B, O’Keeffe B, et al. Coronary angioplasty in the United Kingdom. Br Heart J. 1991; 66: 325–31.
23. Loubeyre C, Morice MC, Berzin B, et al. Emergency coronary artery bypass surgery following coronary angioplasty and stenting: results of a French multicenter registry. Catheter Cardiovasc Interv. 1999; 47: 441–8.[CrossRef][Medline] [Order article via Infotrieve]
24. Vogt A, Bonzel T, Harmjanz D, et al. PTCA registry of German community hospitals. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK) Study Group. Eur Heart J. 1997; 18: 1110–4.
25. Dellavalle A, Steffenino G, Ribichini F, Russo P, Uslenghi E. Elective coronary angioplasty with and without surgical standby: clinical and angiographic criteria for the selection of patients. Coron Artery Dis. 1995; 6: 513–20.[Medline] [Order article via Infotrieve]
26. Richardson SG, Morton P, Murtagh JG, O’Keeffe DB, Murphy P, Scott ME. Management of acute coronary occlusion during percutaneous transluminal coronary angioplasty: experience of complications in a hospital without on site facilities for cardiac surgery [see comments]. BMJ. 1990; 300: 355–8.
27. Reifart N, Preusler W, Schwarz F, et al. A large center experience of coronary angioplasty without on-site surgical standby. In: Topol EJ, Serruys PW, editors. Current Review of Interventional Cardiology. Philadelphia: Current Medicine, 1995: 296–303.
28. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991; 266: 93–8.
29. Wennberg DE, Lucas FL, Siewers AE, Kellett MA, Malenka DJ. Outcomes of percutaneous coronary interventions performed at centers without and with onsite coronary artery bypass graft surgery. JAMA. 2004; 292: 1961–8.
30. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002; 360: 743–51.[CrossRef][Medline] [Order article via Infotrieve]
31. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. 2004; 43: 1743–51.
32. Chieffo A, Stankovic G, Bonizzoni E, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation. 2005; 111: 791–5.
33. Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol. 2005; 45: 351–6.
34. Silvestri M, Barragan P, Sainsous J, et al. Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol. 2000; 35: 1543–50.
35. Tan WA, Tamai H, Park SJ, et al. Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. Circulation. 2001; 104: 1609–14.
36. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. 2004; 44: 1146–310.
37. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) 2002. Available at: http://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm. Accessed January 10, 2005.
38. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999; 354: 708–15.[CrossRef][Medline] [Order article via Infotrieve]
39. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001; 344: 1879–87.
40. de Lezo JS, Medina A, Pan M, et al. Rapamycin-eluting stents for the treatment of unprotected left main coronary disease. Am Heart J. 2004; 148: 481–5.[CrossRef][Medline] [Order article via Infotrieve]
41. Black A, Cortina R, Bossi I, Choussat R, Fajadet J, Marco J. Unprotected left main coronary artery stenting: correlates of midterm survival and impact of patient selection. J Am Coll Cardiol. 2001; 37: 832–8.
42. Takagi T, Stankovic G, Finci L, et al. Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation. 2002; 106: 698–702.
43. Park SJ, Park SW, Hong MK, et al. Long-term (three-year) outcomes after stenting of unprotected left main coronary artery stenosis in patients with normal left ventricular function. Am J Cardiol. 2003; 91: 12–6.[Medline] [Order article via Infotrieve]
44. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361: 13–20.[CrossRef][Medline] [Order article via Infotrieve]
45. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol. 2003; 92: 824–6.[CrossRef][Medline] [Order article via Infotrieve]
46. De LG, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004; 109: 1223–5.
47. Berger PB, Ellis SG, Holmes DR, Jr., et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation. 1999; 100: 14–20.
48. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock [see comments]. N Engl J Med. 1999; 341: 625–34.
49. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001; 285: 190–2.
50. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J. 1999; 20: 1030–8.
51. Dzavik V, Sleeper LA, Picard MH, et al. Outcome of patients aged >or=75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? Am Heart J. 2005; 149: 1128–34.[CrossRef][Medline] [Order article via Infotrieve]
52. Dauerman HL, Goldberg RJ, Malinski M, Yarzebski J, Lessard D, Gore JM. Outcomes and early revascularization for patients >or= 65 years of age with cardiogenic shock. Am J Cardiol. 2001; 87: 844–8.[CrossRef][Medline] [Order article via Infotrieve]
53. Dauerman HL, Ryan TJ, Jr., Piper WD, et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol. 2003; 15: 380–4.[Medline] [Order article via Infotrieve]
54. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002; 40: 1389–94.
55. Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol. 1992; 20: 1482–9.[Abstract]
56. Lee L, Erbel R, Brown TM, Laufer N, Meyer J, O’Neill WW. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. J Am Coll Cardiol. 1991; 17: 599–603.[Abstract]
57. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001; 344: 1895–903.
58. Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol. 2000; 85: 13–8.[Medline] [Order article via Infotrieve]
59. Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation. 2001; 104: 642–7.
60. Gibson CM. A union in reperfusion: the concept of facilitated percutaneous coronary intervention. J Am Coll Cardiol. 2000; 36: 1497–9.
61. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol. 2000; 36: 1489–96.
62. Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA. 2004; 291: 947–54.
63. Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol. 2005; 46: 417–24.
64. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation. 1997; 96: 748–55.
65. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002; 105: 1285–90.
66. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 2003; 108: 548–53.
67. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502.
68. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358: 527–33.[CrossRef][Medline] [Order article via Infotrieve]
69. Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411–20.
70. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004; 109: 1942–7.
71. Holmes DR, Jr., Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004; 109: 634–40.
72. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di SG. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005; 111: 2099–106.
73. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004; 350: 232–8.
74. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005; 111: 1153–9.
75. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998; 98: 734–41.
76. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000; 35: 915–21.
77. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002; 346: 957–66.
78. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol. 1998; 31: 1234–9.
79. Kong DF, Hasselblad V, Harrington RA, et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 2003; 92: 651–5.[CrossRef][Medline] [Order article via Infotrieve]
80. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003; 41: 26–32.
81. Angiomax (bivalirudin) for injection. Package Insert. The Medicine Company, Parsippany, NJ. Available at: http://www.themedicinescompany.com/~products_content/PN16019gt2.pdf. Accessed May 27, 2005.
82. Argatroban Injection. Prescribing Information. GlaxoSmithKline, Research Triangle, NC. Available at: http://us.gsk.com/products/assets/us_argatroban.pdf. Accessed May 27, 2005.
83. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289: 853–63.
84. Erbel R, Haude M, Hopp HW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group [see comments]. N Engl J Med. 1998; 339: 1672–8.
85. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104: 2007–11.
86. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773–80.
87. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004; 43: 1110–5.
88. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003; 362: 1093–9.[CrossRef][Medline] [Order article via Infotrieve]
89. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol. 2003; 41: 2093–9.
90. Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004; 43: 704–8.
91. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the ‘real world‘: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004; 109: 190–5.
92. Hoye A, Tanabe K, Lemos PA, et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol. 2004; 43: 1954–8.
93. Liistro F, Stankovic G, Di MC, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation. 2002; 105: 1883–6.
94. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003; 348: 1537–45.
95. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003; 107: 38–42.
96. Colombo A, Orlic D, Stankovic G, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation. 2003; 107: 2178–80.
97. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003; 107: 559–64.
98. Kastrati A, Mehilli J, von BN, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005; 293: 165–71.
99. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2003; 107: 24–7.
100. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol. 2003; 41: 184–9.
101. Neumann FJ, Desmet W, Grube E, et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation. 2005; 111: 2107–11.
102. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997; 336: 1697–703.
103. Raizner AE, Oesterle SN, Waksman R, et al. Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation. 2000; 102: 951–8.
104. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. 2000; 101: 2165–71.
105. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001; 344: 250–6.
106. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet. 2002; 359: 551–7.[CrossRef][Medline] [Order article via Infotrieve]
107. Popma JJ, Suntharalingam M, Lansky AJ, et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation. 2002; 106: 1090–6.
108. Waksman R, Ajani AE, White RL, et al. Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med. 2002; 346: 1194–9.
109. Waksman R, Cheneau E, Ajani AE, et al. Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies. Circulation. 2003; 107: 1744–9.
Related Internet Resources:
- 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
This article has been cited by other articles:
 |
|
 |
|
  A. Kumar and C. P. Cannon Acute Coronary Syndromes: Diagnosis and Management, Part II Mayo Clin. Proc., November 1, 2009; 84(11): 1021 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 CardioPulse Articles Eur. Heart J., September 2, 2009; 30(18): 2165 - 2173. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Collet and G. Montalescot Review: Platelet Function Testing and Implications for Clinical Practice Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2009; 14(3): 157 - 169. [Abstract] [PDF]
|
|
|
|
|
|
A. D. Michelson, A. L. Frelinger III, E. Braunwald, W. E. Downey, D. J. Angiolillo, N. P. Xenopoulos, J. A. Jakubowski, Y. Li, S. A. Murphy, J. Qin, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur. Heart J., July 2, 2009; 30(14): 1753 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Onuma, N. Kukreja, J. Daemen, H. M. Garcia-Garcia, N. Gonzalo, J. M. Cheng, P. H. van Twisk, R. van Domburg, P. W. Serruys, and on behalf of the Interventional Cardiologists of T Impact of Sex on 3-Year Outcome After Percutaneous Coronary Intervention Using Bare-Metal and Drug-Eluting Stents in Previously Untreated Coronary Artery Disease: Insights From the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries J. Am. Coll. Cardiol. Intv., July 1, 2009; 2(7): 603 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Busk, A. Kaltoft, S. S. Nielsen, M. Bottcher, M. Rehling, L. Thuesen, H. E. Botker, J. F. Lassen, E. H. Christiansen, L. R. Krusell, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs. 12-72 h Eur. Heart J., June 1, 2009; 30(11): 1322 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tousoulis, A. Briasoulis, S. S Dhamrait, C. Antoniades, and C. Stefanadis Effective platelet inhibition by aspirin and clopidogrel: where are we now? Heart, May 1, 2009; 95(10): 850 - 858. [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Donnan and S. M. Davis Combined Aspirin Plus Warfarin: Recent Evidence and Residual Questions Stroke, May 1, 2009; 40(5): 1946 - 1946. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Eisenberg, P. R. Richard, D. Libersan, and K. B. Filion Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents Circulation, March 31, 2009; 119(12): 1634 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif, P. Ponikowski, T. Kahan, and for the ASSOCIATE study Investigators Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial Eur. Heart J., March 1, 2009; 30(5): 540 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Smith Surgery, Not Percutaneous Revascularization, Is the Preferred Strategy for Patients With Significant Left Main Coronary Stenosis Circulation, February 24, 2009; 119(7): 1013 - 1020. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Teirstein Percutaneous Revascularization Is the Preferred Strategy for Patients With Significant Left Main Coronary Stenosis Circulation, February 24, 2009; 119(7): 1021 - 1033. [Full Text] [PDF]
|
|
|
|
|
|
R. Iijima, G. Ndrepepa, J. Mehilli, R. A. Byrne, S. Schulz, F.-J. Neumann, G. Richardt, P. B. Berger, A. Schomig, and A. Kastrati Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention Eur. Heart J., February 1, 2009; 30(3): 290 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.L. Lucas, A.E. Siewers, D.J. Malenka, and D.E. Wennberg Diagnostic-Therapeutic Cascade Revisited: Coronary Angiography, Coronary Artery Bypass Graft Surgery, and Percutaneous Coronary Intervention in the Modern Era Circulation, December 16, 2008; 118(25): 2797 - 2802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Shemin Coronary Artery Bypass Grafting Versus Stenting for Unprotected Left Main Coronary Artery Disease: Where Lies the Body of Proof? Circulation, December 2, 2008; 118(23): 2326 - 2329. [Full Text] [PDF]
|
|
|
|
|
|
J. Rodes-Cabau, J. DeBlois, O. F. Bertrand, S. Mohammadi, J. Courtis, E. Larose, F. Dagenais, J.-P. Dery, P. Mathieu, M. Rousseau, et al. Nonrandomized Comparison of Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention for the Treatment of Unprotected Left Main Coronary Artery Disease in Octogenarians Circulation, December 2, 2008; 118(23): 2374 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Piers, R. Dikkers, T. P. Willems, B. J.G.L. de Smet, M. Oudkerk, F. Zijlstra, and R. A. Tio Computed tomographic angiography or conventional coronary angiography in therapeutic decision-making Eur. Heart J., December 1, 2008; 29(23): 2902 - 2907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Miller, C. E. Rochitte, M. Dewey, A. Arbab-Zadeh, H. Niinuma, I. Gottlieb, N. Paul, M. E. Clouse, E. P. Shapiro, J. Hoe, et al. Diagnostic Performance of Coronary Angiography by 64-Row CT N. Engl. J. Med., November 27, 2008; 359(22): 2324 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Gibbons Noninvasive Diagnosis and Prognosis Assessment in Chronic Coronary Artery Disease: Stress Testing With and Without Imaging Perspective Circ Cardiovasc Imaging, November 1, 2008; 1(3): 257 - 269. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Rudolph, T. K. Rudolph, F. J. Schopfer, G. Bonacci, D. Lau, K. Szocs, A. Klinke, T. Meinertz, B. A. Freeman, and S. Baldus Bivalirudin Decreases NO Bioavailability by Vascular Immobilization of Myeloperoxidase J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 324 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wu, E. L. Hannan, G. Walford, and D. P. Faxon Utilization and Outcomes of Unprotected Left Main Coronary Artery Stenting and Coronary Artery Bypass Graft Surgery Ann. Thorac. Surg., October 1, 2008; 86(4): 1153 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Bass and P. Capranzano Managing Patients With Intermediate In-Stent Restenotic Lesions: Is It "Prime Time" for Intravascular Ultrasound Imaging? Circ Cardiovasc Interv, October 1, 2008; 1(2): 90 - 92. [Full Text] [PDF]
|
|
|
|
|
|
T. Kimura, T. Morimoto, Y. Furukawa, Y. Nakagawa, S. Shizuta, N. Ehara, R. Taniguchi, T. Doi, K. Nishiyama, N. Ozasa, et al. Long-Term Outcomes of Coronary-Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Multivessel Coronary Artery Disease in the Bare-Metal Stent Era Circulation, September 30, 2008; 118(14_suppl_1): S199 - S209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Weintraub, W. E. Boden, Z. Zhang, P. Kolm, Z. Zhang, J. A. Spertus, P. Hartigan, E. Veledar, C. Jurkovitz, J. Bowen, et al. Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients Circ Cardiovasc Qual Outcomes, September 1, 2008; 1(1): 12 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chieffo, S.-J. Park, E. Meliga, I. Sheiban, M. S. Lee, A. Latib, Y.-H. Kim, M. Valgimigli, D. Sillano, V. Magni, et al. Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry Eur. Heart J., September 1, 2008; 29(17): 2108 - 2115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Weintraub, J. A. Spertus, P. Kolm, D. J. Maron, Z. Zhang, C. Jurkovitz, W. Zhang, P. M. Hartigan, C. Lewis, E. Veledar, et al. Effect of PCI on Quality of Life in Patients with Stable Coronary Disease N. Engl. J. Med., August 14, 2008; 359(7): 677 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Lee, C.-H. Tseng, C. M. Barker, V. Menon, D. Steckman, R. Shemin, and J. S. Hochman Outcome After Surgery and Percutaneous Intervention for Cardiogenic Shock and Left Main Disease Ann. Thorac. Surg., July 1, 2008; 86(1): 29 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Tejada, F. Hernandez, J. Chimeno, M. A. Alonso, R. Martin, and T. Bastante Acute Pancreatitis Mimicking Acute Inferior Myocardial Infarction Angiology, July 1, 2008; 59(3): 365 - 367. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Zellweger, C. Kaiser, H. P. Brunner-La Rocca, P. T. Buser, S. Osswald, P. Weiss, J. Mueller-Brand, M. E. Pfisterer, and for the BASKET Investigators Value and Limitations of Target-Vessel Ischemia in Predicting Late Clinical Events After Drug-Eluting Stent Implantation J. Nucl. Med., April 1, 2008; 49(4): 550 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Michelson P2Y12 Antagonism: Promises and Challenges Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s33 - s38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Zahn, M Gottwik, M Hochadel, J Senges, U Zeymer, A Vogt, T Meinertz, R Dietz, K E Hauptmann, E Grube, et al. Volume-outcome relation for contemporary percutaneous coronary interventions (PCI) in daily clinical practice: is it limited to high-risk patients? Results from the Registry of Percutaneous Coronary Interventions of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK) Heart, March 1, 2008; 94(3): 329 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Qayyum, M. R. Khalid, J. Adomaityte, S. P. Papadakos, and F. C. Messineo Systematic Review: Comparing Routine and Selective Invasive Strategies for the Acute Coronary Syndrome Ann Intern Med, February 5, 2008; 148(3): 186 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gibbons and S. D. Fihn Coronary Revascularization: New Evidence, New Challenges Ann Intern Med, November 20, 2007; 147(10): 732 - 734. [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Diamond and S. Kaul COURAGE Under Fire: On the Management of Stable Coronary Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1604 - 1609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colombo and A. Chieffo Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease) Circulation, September 18, 2007; 116(12): 1424 - 1432. [Full Text] [PDF]
|
|
|
|
|
|
J. Daemen and P. W. Serruys Drug-Eluting Stent Update 2007: Part II: Unsettled Issues Circulation, August 21, 2007; 116(8): 961 - 968. [Full Text] [PDF]
|
|
|
|
|
|
F. Airoldi, A. Colombo, N. Morici, A. Latib, J. Cosgrave, L. Buellesfeld, E. Bonizzoni, M. Carlino, U. Gerckens, C. Godino, et al. Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment Circulation, August 14, 2007; 116(7): 745 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Moscucci Behavioral Factors, Bias, and Practice Guidelines in the Decision to Use Percutaneous Coronary Interventions for Stable Coronary Artery Disease Arch Intern Med, August 13, 2007; 167(15): 1573 - 1575. [Full Text] [PDF]
|
|
|
|
|
|
T. C. Gerber, B. Kantor, and P. Chareonthaitawee Coronary computed tomographic angiography and exercise electrocardiography: a great match or unequal partners? Eur. Heart J., August 1, 2007; 28(15): 1787 - 1789. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bode Introduction Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D1 - D2. [Full Text] [PDF]
|
|
|
|
|
|
C. Bode and M. Zehender The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D10 - D19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Granger, T. D. Henry, W. E. R. Bates, B. Cercek, W. D. Weaver, and D. O. Williams Development of Systems of Care for ST-Elevation Myocardial Infarction Patients: The Primary Percutaneous Coronary Intervention (ST-Elevation Myocardial Infarction Receiving) Hospital Perspective Circulation, July 10, 2007; 116(2): e55 - e59. [Full Text] [PDF]
|
|
|
|
|
|
A. Chieffo, S. J. Park, M. Valgimigli, Y. H. Kim, J. Daemen, I. Sheiban, A. Truffa, M. Montorfano, F. Airoldi, G. Sangiorgi, et al. Favorable Long-Term Outcome After Drug-Eluting Stent Implantation in Nonbifurcation Lesions That Involve Unprotected Left Main Coronary Artery: A Multicenter Registry Circulation, July 10, 2007; 116(2): 158 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Krucoff, A. Boam, and D. G. Schultz Drug-Eluting Stents "Deliver Heartburn": How Do We Spell Relief Going Forward? Circulation, June 12, 2007; 115(23): 2990 - 2994. [Full Text] [PDF]
|
|
|
|
|
|
N. H.J. Pijls, P. van Schaardenburgh, G. Manoharan, E. Boersma, J.-W. Bech, M. van't Veer, F. Bar, J. Hoorntje, J. Koolen, W. Wijns, et al. Percutaneous Coronary Intervention of Functionally Nonsignificant Stenosis: 5-Year Follow-Up of the DEFER Study J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2105 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gaemperli, T. Schepis, I. Valenta, L. Husmann, H. Scheffel, V. Duerst, F. R. Eberli, T. F. Luscher, H. Alkadhi, and P. A. Kaufmann Cardiac Image Fusion from Stand-Alone SPECT and CT: Clinical Experience J. Nucl. Med., May 1, 2007; 48(5): 696 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Abbate, G. G.L. Biondi-Zoccai, P. Agostoni, M. J. Lipinski, and G. W. Vetrovec Recurrent angina after coronary revascularization: a clinical challenge Eur. Heart J., May 1, 2007; 28(9): 1057 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Boden, R. A. O'Rourke, K. K. Teo, P. M. Hartigan, D. J. Maron, W. J. Kostuk, M. Knudtson, M. Dada, P. Casperson, C. L. Harris, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease N. Engl. J. Med., April 12, 2007; 356(15): 1503 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Maisel Unanswered Questions -- Drug-Eluting Stents and the Risk of Late Thrombosis N. Engl. J. Med., March 8, 2007; 356(10): 981 - 984. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, S. B. Shoemaker, B. Desai, H. Yuan, R. K. Charlton, E. Bernardo, M. M. Zenni, L. A. Guzman, T. A. Bass, and M. A. Costa Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study Circulation, February 13, 2007; 115(6): 708 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Burton, I. Burton, and G. J Pearson Clopidogrel-Precipitated Rhabdomyolysis in a Stable Heart Transplant Patient Ann. Pharmacother., January 1, 2007; 41(1): 133 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease) Circulation, December 19, 2006; 114(25): 2850 - 2870. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Taggart Coronary Artery Bypass Grafting is Still the Best Treatment for Multivessel and Left Main Disease, But Patients Need to Know Ann. Thorac. Surg., December 1, 2006; 82(6): 1966 - 1975. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J Y Sung Combining aspirin with antithrombotic agents. BMJ, October 7, 2006; 333(7571): 712 - 713. [Full Text] [PDF]
|
|
|
|
|
|
C. Spaulding, M.-C. Morice, B. Lancelin, S. El Haddad, E. Lepage, S. Bataille, J.-P. Tresca, X. Mouranche, S. Fosse, M. Monchi, et al. Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry Eur. Heart J., May 1, 2006; 27(9): 1054 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Jacobs Regionalized Care for Patients With ST-Elevation Myocardial Infarction: It's Closer Than You Think Circulation, March 7, 2006; 113(9): 1159 - 1161. [Full Text] [PDF]
|
|
|
|
 |
|
 Guidelines: Percutaneous Coronary Intervention Journal Watch Cardiology, January 12, 2006; 2006(112): 2 - 2. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||